Animal Models for Nonclinical Safety Assessment
December 6, 2017
Speaker: Sherry J. Morgan
Educational Levels: Advanced, Emerging
Considerations for the use of animal models of disease will be discussed with specific examples of organ systems and/or responses that are generally either well or poorly predicted with the use of conventional animal models. The results of a recent survey (IQ Focus Group) that queried the current practices as it pertains to the use of animal models in nonclinical safety assessment will be presented. Attention will be given to differentiating the use of animal models of disease in discovery vs. development as well as describing common themes across industries.
This presentation was sponsored by AbbVie. AbbVie contributed to the design, research, and interpretation of data, writing, reviewing, and approving the publication. Sherry Morgan is an employee of AbbVie.
-
Animal Models for Nonclinical Safety Assessment: Pharmaceutical Industry Survey
The approach for the nonclinical safety assessment of prophylactic vaccines for infectious diseases is well-established, with several regulatory guidelines and numerous examples of toxicology studies available in the literature and product approval packages. In contrast, there are few regulatory ...
